Yunjian Medicine Announces Completion of Series B1 Financing to Advance Mass Spectrometry-Based Proteomics and Big Data-Driven Development Platform and Accelerate Commercialization

VCBeat has learned at the earliest opportunity,Yunjian Medical Group(hereinafter referred to as"Yunjian Medical") ObtainAstraZeneca CICC Healthcare Industry FundB1RoundExclusive Investment. This round of financing is primarily used to furtherExpand the Company's Product Portfolio in Maternal and Child HealthandCancer Detection Product R&D Pipeline, and continuously advance each product line inRegistration and Manufacturing in China and the United States、Commercialization and expansion into international markets.

Yunjian Medical is a next-generation platform company based on protein and metabolomics biomarker discovery technologies.Since its establishment in 2015, the company has built a unique analysis platform driven by medical hypotheses and based on mass spectrometry-based proteomics and big data. This platform has shortened the cycle for discovering disease biomarkers compared to traditional methods and adapts corresponding clinical diagnostic platforms according to biomarker characteristics, thereby achieving a closed-loop pathway for rapid product commercialization. Currently, the company is rapidly advancing the registration and commercialization of IVD/LDT products in China, the United States, Japan, and other regions, focusing on women’s and maternal health, pediatric rare disease testing, precision cancer diagnosis and recurrence monitoring, and innovative testing for metabolic diseases.

Yunjian Medical’s platform technology innovations stem from over 19 years of accumulation by an R&D team with backgrounds from Stanford University School of Medicine. The founding team possesses extensive experience in drug development, discovery of disease biomarkers, clinical translation and diagnostics, big data disease modeling, and data security. Currently, the company has established dual R&D centers and GMP-compliant manufacturing facilities in both China and the United States, located in Maryland and California (US), as well as Shanghai, Tianjin, and Chengdu (China). In Maryland, it operates a CAP/CLIA-certified clinical laboratory accredited by both the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). Meanwhile, Tianjin Yunjian Medical Laboratory has obtained the Chinese Medical Institution Practice License, and through double-blind comparative studies, its testing items have achieved quality levels equivalent to CAP standards.

At the recently concluded Wuxi Taihu Bay Life and Health Future Conference, Yunjian Medical announced an exploratory research collaboration with AstraZeneca in the fields of proteomics and metabolomics, including but not limited to the detection of common innovative drug targets in drug development using mass spectrometry-based targeted technologies. Yunjian Medical will provide AstraZeneca with mass spectrometry-driven companion diagnostic tests for innovative drug development, facilitating the precise identification of more effective patient populations and the optimization of clinical trial protocols.

Mr. Chen Limin, Co-founder and CEO of Yunjian MedicalYunjian Medical stated: “As a high-tech enterprise driven by innovation, Yunjian Medical has always been committed to providing better medical products and services for clinical practice and patients in the field of serious healthcare. Leveraging the technical expertise of its Stanford University team and successful overseas operational experience, Yunjian Medical has established a solid technological foundation and a rich product pipeline, dedicated to offering maternal and child health and cancer screening, testing, and tracking solutions globally. Standing at a new starting point, Yunjian Medical not only pursues commercial success but is also committed to exploring and practicing the Chinese path of ‘Artificial Intelligence + Multi-omics Testing,’ integrating its product pipelines into the national strategy of ‘Healthy China Action.’ We sincerely thank AstraZeneca for its trust and support in Yunjian Medical. We look forward to working hand in hand with investors and partners to achieve mutual growth.”

Mr. Chen Bing, Managing Director of the AstraZeneca CICC Healthcare Industry Fund, and Vice President of AstraZeneca China, Head of Strategic Collaboration and Business Developmentstated: “Although mass spectrometry platforms have been successfully commercialized in overseas research fields for many years, their applications in China’s clinical diagnostics sector are largely confined to traditional biomarkers, and market penetration remains constrained by complex pre-analytical workflows. Leveraging its years of accumulation in omics data and disease modeling, Yunjian Medical has built a ‘Mass Spectrometry-Based Proteomics and Big Data-Driven Development Platform,’ which has reinvigorated traditional research-oriented mass spectrometry platforms. The U.S. R&D team of Yunjian Medical has collaborated multiple times with AstraZeneca’s Global Translational Medicine team, and we look forward to the upcoming exploratory research collaboration between our company and AstraZeneca China.”

Mr. Shan Junbao, President of CICC Capital and Appointed Representative of the Executive Partner of the AstraZeneca-CICC Healthcare Industry Fund“Yunjian Medical boasts advanced technology, a robust team, and a rich product pipeline. Since its inception, the company has developed sufficient capability to provide precise and accessible multi-faceted solutions for clinical practice. We believe that, under the leadership of its scientific team, the company will continue to lead the development of the ‘AI + multi-omics testing’ industry, benefiting more patients across various disease areas, including oncology and women’s and children’s health. We are confident that Yunjian’s global vision, academic foresight, and R&D strength will continuously deliver superior diagnostic tools to clinical practice, thereby benefiting more patients. It is a great honor to participate in this round of financing. We will fully leverage the industrial and financial resources of our fund to comprehensively support the company’s future development.”

The AstraZeneca CICC Healthcare Industry Fund is a private equity fund jointly established by AstraZeneca and CICC Capital, specializing in investments within the healthcare sector. Leveraging AstraZeneca’s global industrial strengths and CICC Capital’s extensive experience in capital operations, the fund focuses on investment areas such as biopharmaceuticals, medical devices, diagnostic services, and digital health. It is committed to integrating industrial and financial resources to provide comprehensive, full-cycle empowerment to enterprises and investment partners, thereby jointly fostering innovative development in China’s healthcare industry.